Ensartinib is a unique, potent ALK inhibitor that has promising clinical activity and low toxicity in patients with ALK-rearranged NSCLC, most of whom had CNS metastases and had previous ALK-TKI treatment. Further study is needed to determine its role as either an initial or post-resistance therapy in ALK-rearranged NSCLC or other types of cancers. READ ARTICLE
Chinese Clinical Oncology DOI: 10.21037/cco.2018.10.12
Author: Tianhong Li, Weijie Ma, Eddie C. Tian